Cory Schwartz
Director, Drug Discovery iBio
Cory Schwartz, PhD, is Director of Drug Discovery at iBio, Inc., where he leads early-stage programs from target identification to candidate selection, leveraging AI-driven antibody discovery and strategic CRO partnerships. A skilled translational scientist, he bridges cutting-edge genome engineering with biologics development, having pioneered CRISPR-based metabolic engineering during his PhD at UC Riverside, where he developed high-throughput strain optimization platforms integrating NGS and bioinformatics.
Previously, as Senior Scientist at Pfenex Inc., Cory spearheaded their lead haematology program (PF901), designing screening cascades for single-domain antibodies and establishing automated hit-to-lead workflows. His expertise spans protein expression, antibody engineering, and AI-aided drug discovery, with a focus on accelerating biologics development through innovative platforms.
Seminars
- Integrating myostatin/activin inhibitors with GLP-1 agonists to preserve metabolic health and enhance long-term patient outcomes
- Leveraging biomarkers & phenotyping to guide patient stratification for combination therapies to identify responders to specific mechanisms
- Designing adaptive trials for multi targeted therapies to enable dosing optimisation and combination ratios for improved efficacy and tolerability
Join this session to explore how obesity trials and treatment paradigms must evolve with GLP-1 agonists as the new backbone therapy. Experts will debate optimal approaches for testing combinations and sequencing therapies, addressing critical questions about trial design, phenotypic targeting, and weight rebound mitigation.
- Determining patient-centric cardiometabolic endpoints to extend beyond weight loss while satisfying payer demands
- Combining dual GLP-1 and myostatin inhibitors to reduce muscle mass loss for greater metabolic health and explore composite endpoints that reflect real-world patient priorities to lower trial dropout rates
- Exploring sequential therapy protocols to reduce GI side effects for improved long-term adherence
- Reducing weight cycling by shifting focus from acute weight loss to sustained metabolic outcomes
- Extended half-life reduces dosing frequency and injection volume and improves patient experience
- Myostatin inhibition can minimise lean mass loss during weight loss on GLP-1s
- Precision targeting of additional TGF-beta superfamily members could enable further improvements in weight loss quality
